Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27602261 | 0.84 | NPSR1 (0.58) | NPSR1ALDH1A1HTTHSD17B10TDP1 | |
| SCHEMBL29931026 | 0.84 | NPSR1 (0.58) | NPSR1ALDH1A1HTTHSD17B10TDP1 | |
| SCHEMBL1695081 | 0.84 | NPSR1 (0.58) | NPSR1ALDH1A1HTTHSD17B10TDP1 | |
| SCHEMBL22090177 | 0.83 | NPSR1 (0.60) | NPSR1ALDH1A1HTTHSD17B10TDP1 | |
| SCHEMBL19130275 | 0.81 | NPSR1 (0.55) | NPSR1ALDH1A1HTTHSD17B10TDP1 | |
| SCHEMBL6809337 | 0.81 | NPSR1 (0.55) | NPSR1ALDH1A1HTTHSD17B10TDP1 | |
| SCHEMBL4009144 | 0.81 | NPSR1 (0.77) | NPSR1ALDH1A1HTTHSD17B10TDP1 | |
| SCHEMBL2956140 | 0.79 | NPSR1 (0.60) | NPSR1ALDH1A1HTTHSD17B10TDP1 | |
| SCHEMBL8331183 | 0.79 | NPSR1 (0.60) | NPSR1ALDH1A1HTTHSD17B10TDP1 | |
| SCHEMBL27651146 | 0.79 | NPSR1 (0.56) | NPSR1ALDH1A1HTTHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024185697-A1 | METHOD FOR PRODUCING POLYNUCLEOTIDE LINKED PRODUCT | 国立大学法人東海国立大学機構 | 2024-09-12 | — | — | WO | disclosed |
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | NANJING HEPO PHARMACEUTICAL CO., LTD (CN) | 2023-05-30 | — | — | US | disclosed |
| CN-103736099-A | Prodrug with nitrophenyl alkyl acid connected with alkaline antitumor drugs and preparation method thereof | UNIV BEIJING | 2014-04-23 | — | — | CN | disclosed |
| WO-2009080682-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080682-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| US-6130237-A | Condensed N-aclyindoles as antitumor agents | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-10-10 | — | — | US | disclosed |
| EP-0938474-A2 | CYCLOPROPYLINDOLE COMPOUNDS AND THEIR USE AS PRODRUGS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998011101-A2 | CONDENSED N-ACLYINDOLES AS ANTITUMOR AGENTS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661420-B2 | Compound containing fused ring, use thereof and pharmaceutical composition containing same | HLA-B, HLA-A, SLC10A1 | NPSR1 4510/4885ALDH1A1 2801/4885HTT 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.